Editorial Board

Prof. Meser M. Ali, PhD

Prof. Meser M. Ali, PhD
Director, Cellular and Molecular Imaging lab
Associate Scientist, Department of Neurosurgery, Henry Ford Hospital
Wayne State University

Biography :

Meser M. Ali received his Ph.D. degree in Organometallic Chemistry from Mie University in Japan in 1999. He is an Associate Scientist in the Department of Neurosurgery, and Director, Cellular and Molecular Imaging laboratory, Henry Ford Hospital, Detroit, Michigan, USA. He is also an Associate Professor (adjunct) in the Department of Chemical Engineering and Material Science, Wayne State University, Detroit, Michigan, USA. His research program focuses on the development of small-sized nanomedicine that can cross tumor blood brain barrier for potential applications of brain cancer imaging and therapy. His research program has been supported by National Institutes of Health (NIH).

Research Interest :

My research interest is in the discipline of nanomedicine and drug delivery with noninvasive molecular imaging. Nanomedicine, carrying therapeutic payloads and delivered within close proximity of the tumor, can be designed to play a significant role in increasing treatment effectiveness while decreasing severity of side effects. Specifically, my research work focuses in developing small-sized nanoparticles that can cross tumor blood brain barrier and target primary glioblastoma multiform (GBM) selectively. My work resulted in the development of a series of new dendrimer-based multifunctional nanoparticles that are detected by standard MR relativity methods or new MRI methods based on Paramagnetic Chemical Exchange Saturation Transfer (PARACEST). My developments of small nano-sized molecular imaging agents that can target GBM selectively. Therefore, primary GBM tumor selective drug delivery and imaging can be accomplished by using these dendrimer-based nanoparticles that possess long blood half-lives. We have reformulated promising anti-cancer drugs that failed to reach clinical trials, or failed in clinical trials due to toxicity or poor bioavailability. These reformulations have reproduced usable, safe therapies using nanoparticles. I have also used state-of-the-art MRI methods to study tumor progression and the early responses to chemotherapies in pre-clinical animal models.